Signaturefd LLC Raises Stock Holdings in Haleon plc (NYSE:HLN)

Signaturefd LLC grew its stake in Haleon plc (NYSE:HLN) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,095 shares of the company’s stock after buying an additional 12,028 shares during the quarter. Signaturefd LLC’s holdings in Haleon were worth $1,289,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of HLN. Natixis Advisors LLC increased its position in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after buying an additional 866,070 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Haleon by 69.0% in the third quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock worth $588,000 after buying an additional 22,701 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Haleon by 3.1% in the third quarter. PNC Financial Services Group Inc. now owns 211,326 shares of the company’s stock worth $2,236,000 after buying an additional 6,381 shares in the last quarter. West Family Investments Inc. purchased a new stake in shares of Haleon during the third quarter worth about $143,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Haleon during the third quarter worth about $57,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HLN. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Six equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Haleon has an average rating of “Hold” and an average price target of $10.95.

Haleon Stock Performance

NYSE HLN opened at $10.30 on Wednesday. The stock has a market capitalization of $46.61 billion, a PE ratio of 30.28, a P/E/G ratio of 2.82 and a beta of 0.25. The business has a 50 day simple moving average of $9.79 and a two-hundred day simple moving average of $9.88. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1-year low of $7.99 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. On average, research analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a dividend yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.